Kiora Pharmaceuticals (KPRX) vs Lisata Therapeutics (LSTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Kiora Pharmaceuticals (KPRX) has outperformed Lisata Therapeutics (LSTA) over the past year, losing 7.3% versus a loss of 52.6%. Over five years, LSTA leads with a -93.4% price change compared with -99.6% for KPRX. Lisata Therapeutics is the larger company by market cap ($11.5 million vs $11.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KPRX | LSTA |
|---|---|---|
| Share price | $2.54 | $1.06 |
| Market cap | $11.24M | $11.45M |
| 1-day change | +0.40% | -11.67% |
| YTD return | +28.43% | -35.48% |
| 1-year return | -7.33% | -52.57% |
| 5-year return | -99.64% | -93.44% |
| EPS (TTM) | $-2.46 | $-1.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.91 | $5.07 |
| 52-week low | $1.77 | $0.99 |
| Distance from 52-week high | -12.71% | -79.09% |
| Analyst consensus | none | none |
| Avg. price target upside | +372.44% | — |
| Average volume | 17.41K | 302.71K |
| Shares outstanding | 4.42M | 10.80M |
| Employees | 13 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KPRX has outperformed LSTA by 45.2 percentage points over the past year.
About Kiora Pharmaceuticals
KPRX stock →Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
About Lisata Therapeutics
LSTA stock →Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
KPRX vs LSTA FAQ
Which is bigger, Kiora Pharmaceuticals or Lisata Therapeutics?
Lisata Therapeutics (LSTA) is larger, with a market capitalization of $11.45M compared with $11.24M for Kiora Pharmaceuticals (KPRX).
Which stock has performed better over the past year, KPRX or LSTA?
KPRX returned -7.33% over the past 12 months, compared with -52.57% for LSTA (price return, excluding dividends). Past performance does not predict future results.
Are Kiora Pharmaceuticals and Lisata Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.